10-K: Stereotaxis Reports Slight Revenue Increase in 2024, Focuses on Strategic Acquisition and Innovation

Stereotaxis reports a marginal revenue increase in 2024, highlighting its acquisition of Access Point Technologies EP, Inc. and ongoing development of robotic systems and disposable devices.

Summary

• Stereotaxis, Inc. reported a slight increase in revenue for the year ended December 31, 2024, with total revenue reaching $26.9 million compared to $26.8 million in the previous year.
• The company's backlog as of December 31, 2024, was approximately $15.2 million, with expectations to recognize around 70% of this as revenue in 2025.
• A key development was the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, aimed at enhancing catheter development and manufacturing capabilities.
• The company is actively pursuing regulatory approvals for its GenesisX RMN System in the U.S. and other countries, and has obtained CE Mark for the Stereotaxis MAGiC catheter in Europe.
• Operating expenses exceeded gross margin in 2024, and the company expects to continue incurring operating losses until revenues sufficiently cover operations or expense reductions are implemented.
• The company's liquidity needs will be largely determined by the success of clinical adoption within the installed base of its robotic magnetic navigation system as well as new placements of capital systems.
• The company plans to improve liquidity conditions primarily through controlling operating expenses and raising additional funds through debt or equity financing.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there's a slight revenue increase and strategic acquisitions, the company is still operating at a loss and faces significant risks. The sentiment is neutral, reflecting both positive developments and ongoing challenges.

Positives

• The acquisition of APT provides in-house catheter development and manufacturing expertise.
• The GenesisX RMN System received CE Mark, enhancing accessibility of robotic magnetic navigation.
• The Stereotaxis MAGiC catheter obtained CE marking in Europe, expanding the product portfolio.
• The company has a universal shelf registration statement for potential future capital raises.
• The company has strategic relationships with technology leaders and innovators in the global interventional market.

Negatives

• The company has sustained operating losses throughout its corporate history and expects that its 2024 operating expenses will exceed its 2024 gross margin.
• The company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place.
• The company may not be able to fund its business operations in the same manner as it has done historically if it does not improve the operating performance of the company or raise additional capital.
• The company may be unable to successfully integrate APT into its business and may fail to realize any or all of the anticipated benefits of the acquisition, or those benefits may take longer to realize than expected.
• The issuance of the Earnout Consideration will result in dilution to the company's stockholders and may adversely affect the company, including the market price of its securities.

Risks

• Macroeconomic and geopolitical factors, as well as pandemics, epidemics or outbreaks of infectious disease could have an adverse effect our supply chain, our hospital customer buying patterns, and our ability to raise capital and could otherwise disrupt our normal business operations.
• The company may not be able to fund its business operations in the same manner as it has done historically if it does not improve the operating performance of the company or raise additional capital.
• Hospital decision-makers may not purchase our robotic magnetic navigation systems or related products or may think that such systems and products are too expensive.
• If the company is unable to fulfill its current purchase orders and other commitments on a timely basis or at all, it may not be able to achieve future sales growth.
• The company will likely experience long and variable sales and installation cycles, which could result in substantial fluctuations in its quarterly results of operations.
• Physicians may not use the company's products if they do not believe they are safe, efficient and effective.
• The company's collaborations with fluoroscopy system manufacturers and providers of catheters and electrophysiology mapping systems or other parties may fail, or the company may not be able to enter additional collaborations in the future.
• The complexity associated with selling, marketing, and distributing products could impair the company's ability to increase revenue.
• The company's marketing strategy is dependent on collaboration with physician thought leaders.
• Physicians may not commit enough time to sufficiently learn the company's system.
• Customers may choose to purchase competing products and not ours.
• If the magnetic fields generated by the company's system are not compatible with, or interfere with, other widely used equipment in the interventional labs, sales of the company's products would be negatively affected.
• The use of the company's products could result in product liability claims that could be expensive, divert management's attention, and harm the company's reputation and business.
• The company has incurred substantial losses in the past and may not be profitable in the future.
• The company's reliance on contract manufacturers and on suppliers, and in some cases, a single supplier, could harm the company's ability to meet demand for its products in a timely manner or within budget.
• Risks associated with international manufacturing and trade could negatively impact the availability and cost of the company's products because materials used to manufacture our magnets, one of our key system components, are sourced from overseas.
• The company may encounter problems at its manufacturing facilities or those of its subcontractors or otherwise experience manufacturing delays that could result in lost revenue.
• The company's growth may place a significant strain on its resources, and if the company fails to manage its growth, its ability to develop, market, and sell its products will be harmed.
• The company may be unable to successfully integrate APT into its business and may fail to realize any or all of the anticipated benefits of the acquisition, or those benefits may take longer to realize than expected.
• The company's future results may be adversely impacted if the company does not effectively manage APTs catheter manufacturing business following the completion of the acquisition.
• The issuance of the Earnout Consideration will result in dilution to the company's stockholders and may adversely affect the company, including the market price of its securities.
• Under certain circumstances, the company may take certain actions to achieve the milestones under the Purchase Agreement that the company would not have undertaken if the company had not completed the acquisition, which may have an adverse effect on the historical business of Stereotaxis.
• The rate of technological innovation of the company's products might not keep pace with the rest of the market.
• Security breaches and other disruptions to the company's information technology infrastructure could interfere with the company's operations, compromise confidential information, and expose the company to liability which could materially adversely impact the company's business and reputation.
• The company may be unable to protect its technology from use by third parties.
• Third parties may assert that the company is infringing their intellectual property rights.
• Expensive intellectual property litigation is frequent in the medical device industry.
• The company may not be able to maintain all the licenses or rights from third parties necessary for the development, manufacture, or marketing of new and existing products.
• The company's products and related technologies can be applied in different medical applications, and the company may fail to focus on the most profitable areas.
• The company may be subject to damages resulting from claims that its employees or the company have wrongfully used or disclosed alleged trade secrets of their former employers.
• Software errors or other defects may be discovered in the company's products.
• If the company or the parties in its strategic collaborations fail to obtain or maintain necessary FDA clearances or approvals for its medical device products, or if such clearances or approvals are delayed, the company will be unable to continue to commercially distribute and market its products.
• If the company's strategic collaborations elect not to or the company fails to obtain regulatory approvals in other countries for products under development, the company will not be able to commercialize these products in those countries.
• The company may fail to comply with continuing regulatory requirements of the FDA and other authorities and become subject to enforcement action, which may include substantial penalties.
• The company's suppliers, subcontractors, or the company may fail to comply with the FDA quality system regulation or other quality standards.
• If the company fails to comply with health care regulations, the company could face substantial penalties and its business, operations and financial condition could be adversely affected.
• Healthcare policy changes, including the potential repeal or amendment of any existing legislation, may have a material adverse effect on the company.
• The application of state certificate of need regulations and compliance by the company's customers with federal and state licensing or other international requirements could substantially limit the company's ability to sell its products and grow its business.
• Hospitals or physicians may be unable to obtain reimbursement from third-party payors for procedures using the company's products, or reimbursement for procedures may be insufficient to recoup the costs of purchasing the company's products.
• The company's costs could substantially increase if the company receives a significant number of warranty claims or have other significant, uninsured liabilities.
• The company's principal stockholders continue to own a large percentage of the company's voting stock, and they could substantially influence matters requiring stockholder approval.
• Future issuances of the company's securities could dilute current stockholders' ownership.
• The company has never paid dividends on its common stock, and the company does not anticipate paying any cash dividends in the foreseeable future.
• The company's certificate of incorporation and bylaws, Delaware law, and one of the company's collaboration agreements contain provisions that could discourage a takeover.
• Evolving regulation of corporate governance and public disclosure may result in additional expenses and continuing uncertainty.
• The company's future operating results may be below securities analysts' or investors' expectations, which could cause the company's stock price to decline.
• The company expects that the price of its common stock could fluctuate substantially, possibly resulting in class action securities litigation.
• If the company fails to continue to meet all applicable NYSE American Market requirements and the NYSE American determines to delist the company's common stock, the delisting could adversely affect the market liquidity of the company's common stock, which would impair the value of your investment and ultimately harm the company's business by limiting its access to equity markets for capital raising.
• The company will incur significant additional stock-based compensation expense over the term of the CEO Performance Award regardless of whether any of the milestones are achieved.
• The company's stockholders may experience substantial dilution upon payout of shares under the CEO Performance Award.
• Certain provisions in the PSU Agreement may discourage a change in control of the Company even if such a transaction would otherwise be beneficial to the company's stockholders.
• The company is highly dependent on the services of Mr. Fischel, and the company's compensation package, including the CEO Performance Award, may fail to retain him.
• General economic conditions could materially adversely impact the company.
• The company maintains its cash at financial institutions, often in balances that exceed federally insured limits.
• The company may lose key personnel or fail to attract and retain replacement or additional personnel.
• The company faces currency and other risks associated with international operations.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The company's liquidity needs will be largely determined by the success of clinical adoption within the installed base of its robotic magnetic navigation system as well as new placements of capital systems. The company plans to improve liquidity conditions primarily through controlling operating expenses and raising additional funds through debt or equity financing.

Industry Context

The medical device market is intensely competitive and characterized by rapid technological advances. Stereotaxis faces competition from traditional catheter-based electrophysiology ablation approaches, as well as companies developing new products for use in electrophysiology and non-electrophysiology interventional procedures.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• It mentions competition from companies like Biosense Webster, but does not offer a detailed assessment of Stereotaxis' performance relative to these competitors.

Legal Proceedings

• The Company is involved from time to time in various lawsuits and claims arising in the normal course of business.
• In 2024, security agreements were executed under the provisions of the Uniform Commercial Code (UCC), and UCC financing statements have been filed by a vendor on underlying inventory for approximately $ 0.6 million.
• We believe the financing statements have been filed without merit, and we are fully contesting the propriety of such actions.

Stakeholder Impact

• Shareholders may experience dilution due to potential issuance of earnout shares related to the APT acquisition.
• Hospitals and physicians may benefit from the enhanced capabilities of the GenesisX RMN System and Stereotaxis MAGiC catheter.
• Employees may be affected by changes in compensation and benefits, as well as potential restructuring related to the APT acquisition.

Next Steps

• Continue pursuing regulatory approvals for GenesisX RMN System and Stereotaxis MAGiC catheter.
• Focus on clinical adoption of robotic magnetic navigation system.
• Control operating expenses and explore additional funding options.
• Integrate APT into Stereotaxis' business and manage catheter manufacturing.

Key Dates